Aims Eisenmenger syndrome (ES) is associated with considerable morbidity and mortality.
Therapeutic strategies have changed during the 2000s in conjunction with an emphasis on …

Objectives To investigate survival in patients with Eisenmenger syndrome based on a
systematic review of the literature and reanalysis of data. We specifically tested the …

Objective Improved diagnostic tools, timely closure of the shunt and a better understanding
of the complexity of Eisenmenger syndrome (ES) have led to improved care and treatment in …

Abstract Aims To characterize contemporary Eisenmenger patients at a large centre for adult
congenital heart disease, assess survival prospects, and identify predictors of death in this …

Background: Eisenmenger syndrome is associated with substantial morbidity and mortality.
There is no consensus, however, on mortality risk stratification. We aimed to investigate …

Aims We aimed to assess the contemporary outcome of Eisenmenger syndrome (ES),
delineate the use of disease targeting therapies (DTT) in these patients and to investigate …

Aims Advanced therapies (prostacyclin analogues, endothelin receptor antagonists) are
successfully used in the treatment of idiopathic pulmonary arterial hypertension. In addition …

Background Little information is available regarding the clinical history and long-term
prognosis of patients with Eisenmenger syndrome without diagnosis until adulthood. The …

Objective—Pulmonary arterial hypertension (PAH), associated with congenital heart disease
(CHD), usually results from a systemic-to-pulmonary shunt. Eisenmenger syndrome (ES) is …

Eisenmenger syndrome (ES) represents the most severe phenotype of pulmonary arterial
hypertension (PAH) associated with congenital heart disease (CHD) and occurs in patients …